Title: Correlation between interleukin- 6 and Creatine kinase - MB in acute coronary syndrome – A hospital based descriptive study
Authors: Dr S.Ranjith Pratap, Dr M.Senthilvelan M.D., Dr K.Baburaj M.D.
DOI: https://dx.doi.org/10.18535/jmscr/v8i11.42
Abstract
Background: Biomarkers are used in the diagnosis, risk stratification, therapeutic decision making and assessment of clinical outcomes of a patient with ACS. Interleukin -6 (IL-6) is a glycoprotein of about 26kDa molecular weight. It is responsible for various activities ranging from proinflammatory activities.
Objectives: 1. To find out the mean IL-6 levels and mean CK-MB levels among the patients with myocardial infarction. 2. To find out the difference in mean IL-6 and Mean CK-MB levels between those suffering from STEMI, NSTEMI and Unstable angina. 3. To correlate IL 6 levels with CK -MB levels among patients with myocardial infarction.
Methodology: The present study was a hospital based descriptive study carried out in the department of medicine, Rajah Muthiah Medical College and Hospital, Annamalai University between September 2018 to October 2020 among the patients admitted with chest pain and ECG changes. All the data collected will be entered into Microsoft excel 2019 and master chart was created. The excel sheet was then imported into SPSS (statistical package for social sciences) version 23 for further analysis
Results: The mean value of Creatine kinase MB among the study participants was found to be 66.78 ± 35.698mg/l. The mean value of Creatine kinase -MB among those with diagnosis STEMI, NSTEMI and unstable angina was found to be statistically significant for each diagnosis. The mean value of IL-6 among the study participants was found to be 56.67 ± 22.761pg/ml. The mean value of IL-6 among those with diagnosis STEMI, NSTEMI and unstable angina was found to be statistically significant for each diagnosis. Both CK MB and IL-6 were strongly positively correlated with R value of 0.8 and P value of < 0.05.
Keywords: Acute coronary syndrome, Cardiac markers, Interleukin – 6, Creatine kinase -MB, STEMI, NSTEMI, Unstable angina.
References
- Malakar AKr, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019 Oct;234(10):16812–23.
- Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India. :16.
- Glass C, Witztum J. Atherosclerosis: The Road Ahead. Cell. 2001 Feb 23;104:503–16.
- Bauersachs R, Zeymer U, Brière J-B, Marre C, Bowrin K, Huelsebeck M. Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review. Cardiovasc Ther. 2019 Nov 26;2019:1–9.
- Morrow DA, Braunwald E. Future of Biomarkers in Acute Coronary Syndromes: Moving Toward a Multimarker Strategy. Circulation. 2003 Jul 22;108(3):250–2.
- Moe KT, Wong P. Current Trends in Diagnostic Biomarkers of Acute Coronary Syndrome. 2010;39(3):7.
- Barton BE. The biological effects of interleukin 6. Med Res Rev. 1996;16(1):87–109.
- Gibler WB, Lewis LM, Erb RE, Makens PK, Kaplan BC, Vaughn RH, et al. Early detection of acute myocardial infarction in patients presenting with chest pain and nondiagnostic ECGs: Serial CK-MB sampling in the emergency department. Ann Emerg Med. 1990 Dec;19(12):1359–66.
- Lin JC, Apple FS, Murakami MM, Luepker RV. Rates of Positive Cardiac Troponin I and Creatine Kinase MB Mass among Patients Hospitalized for Suspected Acute Coronary Syndromes. Clin Chem. 2004 Feb 1;50(2):333–8.
- Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol. 2001 Nov;24(11):701–4.
- Alwi I, Santoso T, Suyono S, Sutrisna B, Kresno SB. The Cut-off Point of Interleukin-6 Level in Acute Coronary Syndrome. 2007;39(4):6.
- Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship Between Interleukin 6 and Mortality in Patients With Unstable Coronary Artery Disease: Effects of an Early Invasive or Noninvasive Strategy. JAMA. 2001 Nov 7;286(17):2107.